ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Durham, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Triple Negative Breast Cancer

Non-Small-Cell Lung Cancer trials near Durham, NC, USA:

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Chapel Hill, North Carolina, United States and 43 other locations

PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC)....

Active, not recruiting
Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Drug: Nab-Paclitaxel
Drug: Cisplatin

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Durham, North Carolina, United States and 126 other locations

The goal of this Phase 1 clinical study is test tumor infiltrating lymphocytes (known as C-TIL051) with NKTR-255 and anti-PD1 therapy for su-...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: C-TIL051

Phase 1

AbelZeta

Raleigh, North Carolina, United States and 3 other locations

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemothe...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Durvalumab
Procedure: Surgery

Phase 3

AstraZeneca
AstraZeneca

Durham, North Carolina, United States and 230 other locations

This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in-...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: encorafenib
Drug: binimetinib

Phase 2

Pfizer
Pfizer

Durham, North Carolina, United States and 157 other locations

This open-label, non-randomized Phase II trial is designed to assess the safety and tolerability of GT103 in combination with pembrolizumab ...

Active, not recruiting
Recurrent Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Drug: GT103
Drug: Pembrolizumab

Phase 2

Jeffrey Clarke

Durham, North Carolina, United States and 5 other locations

This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combina...

Enrolling
Non-Small Cell Lung Cancer
Drug: Oleclumab
Drug: Durvalumab

Phase 3

AstraZeneca
AstraZeneca

Greensboro, North Carolina, United States and 239 other locations

This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alter...

Active, not recruiting
NSCLC
Drug: REGN5093

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Durham, North Carolina, United States and 29 other locations

The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy ...

Enrolling
Metastatic Non-small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Pemetrexed

Phase 3

AstraZeneca
AstraZeneca

Henrico, Virginia, United States and 252 other locations

and recommended phase II dose (RP2D). Subjects with selected solid tumors including non-small cell lung ...

Enrolling
Metastatic Cancer
Advanced Cancer
Biological: Nivolumab
Biological: MEM-288 Intratumoral Injection

Phase 1

Memgen

Durham, North Carolina, United States and 1 other location

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems